Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. (Q40532403)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 September 2015

Language	Label	Description	Also known as
English	Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.	scientific article published on 11 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sebastian Grosicki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kazimierz Kuliczkowski

2

object named as

Kazimierz Kuliczkowski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Marinus H J van Oers

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mario Petrini

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Fritz Offner

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mark-David Levin

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ira Gupta

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jennifer Phillips

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Vanessa Williams

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stephanie Manson

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Steen Lisby

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Christian Geisler

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PROLONG study investigators

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

13 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1370-1379

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00143-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40532403&oldid=1496283464"